|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Département de Nutrition (Dr. Cano), Clinique Résidence du Parc, Marseille, France; Service de Nutrition Clinique (Dr. Pichard), Hôpitaux Universitaire de Genève, Genève, Switzerland; Département de Médecine Aiguë Spécialisée (Mr. Roth and Dr. Pison), CHU, Grenoble, France; Service de Pneumologie (Dr. Court-Fortuné), CHU, Saint-Etienne, France; Service de Biochimie A (Dr. Cynober), AP-HP, Hôtel-Dieu, Paris, France; Service de Réanimation Médicale et dAssistance Respiratoire (Dr. Gérard-Boncompain), HCL, Lyon, France; Service de Pneumologie (Dr. Cuvelier), CHU, Rouen, France; Service de Pneumologie et de Réanimation Respiratoire (Dr. Laaban), AP-HP, Hôtel-Dieu, Paris, France; Service des Maladies Infectieuses (Dr. Melchior), AP-HP, Hôpital Raymond Poincaré, Garches, France; and Service de Réanimation Médicale (Dr. Raphaël), AP-HP, Hôpital Raymond Poincaré, Garches, France.
Correspondance to: Noël J. M. Cano, MD, PhD, Département de Nutrition, Clinique Résidence du Parc, Rue Gaston Berger, 13010 Marseille, France; e-mail: njm.cano{at}wanadoo.fr
Study objective: To determine the predictive factors of morbidity and mortality in patients with end-stage respiratory disease.
Design: Prospective, multicenter cohort study.
Setting: Thirteen outpatient chest clinics within the Association Nationale de Traitement à Domicile de lInsuffisance Respiratoire.
Participants: Stable adult patients with chronic respiratory failure receiving long-term oxygen therapy and/or home mechanical ventilation (n = 446; 182 women and 264 men; aged 68.5 ± 12.1 years [± SD]); Respiratory diseases were COPD in 42.8%, restrictive disorders in 36.3%, mixed respiratory failure in 13.5%, and bronchiectasis in 7.4%. Recruitment was performed during the yearly examination. Patients with neuromuscular diseases and sleeping apnea were excluded.
Measurements and results: Hospitalization days and survival were recorded during a follow-up of 14.3 ± 5.6 months. Body mass index (BMI), serum albumin, and transthyretin levels were considered for their predictive value of outcome, together with demographic data, underlying respiratory disease, respiratory function, hemoglobin, C-reactive protein, smoking habits, oral corticosteroid use, and antibiotic treatment courses. Overall, 1.8 ± 1.7 hospitalizations (cumulative stay, 17.6 ± 27.1 days) were observed in 254 of 446 patients (57%). Independent predictors of hospitalization were oral corticosteroids, FEV1, and plasma C-reactive protein. One-year and 2-year cumulative survivals were 93% and 69%, respectively. Plasma C-reactive protein, BMI, PaO2 on room air, and oral corticosteroids independently predicted survival in multivariate analysis.
Conclusion: Besides established prognosis factors such as FEV1 and PaO2, nutritional depletion as assessed by BMI and overall systemic inflammation as estimated by C-reactive protein appear as major determinants of hospitalization and death risks whatever the end-stage respiratory disease. BMI and C-reactive protein should be included in the monitoring of chronic respiratory failure. Oral corticosteroids as maintenance treatment in patients with end-stage respiratory disease are an independent risk factor of death, and should be avoided in most cases.
Key Words: body mass index C-reactive protein long-term oxygen therapy noninvasive ventilation survival
This article has been cited by other articles:
![]() |
S. P. Haranath, B. S. Park, M. Osborne, S. Budweiser, and R. A. Jorres Body Mass Index in COPD Mortality: Is It All in the Water? Chest, January 1, 2008; 133(1): 318 - 319. [Full Text] [PDF] |
||||
![]() |
M. Alakhras, P. A. Decker, H. F. Nadrous, M. Collazo-Clavell, and J. H. Ryu Body Mass Index and Mortality in Patients With Idiopathic Pulmonary Fibrosis Chest, May 1, 2007; 131(5): 1448 - 1453. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. F. M. Wouters The systemic face of airway diseases: the role of C-reactive protein. Eur. Respir. J., May 1, 2006; 27(5): 877 - 879. [Full Text] [PDF] |
||||
![]() |
J. P. de Torres, E. Cordoba-Lanus, C. Lopez-Aguilar, M. Muros de Fuentes, A. Montejo de Garcini, A. Aguirre-Jaime, B. R. Celli, and C. Casanova C-reactive protein levels and clinically important predictive outcomes in stable COPD patients Eur. Respir. J., May 1, 2006; 27(5): 902 - 907. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Mannino, M. M. Reichert, and K. J. Davis Lung Function Decline and Outcomes in an Adult Population Am. J. Respir. Crit. Care Med., May 1, 2006; 173(9): 985 - 990. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Buhl and S. G. Farmer Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 83 - 93. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |